
Loading, please wait...

Loading, please wait...

Ensuring ophthalmic hydrogel crosslinking safety is a vital step toward creating reliable alternatives to human donor corneas. Currently, the global shortage of donor tissue significantly restricts corneal transplantation procedures. While one donor cornea can occasionally assist two recipients, the supply still fails to meet growing clinical demand. Furthermore, natural grafts carry inherent risks of infection and cellular rejection. Therefore, researchers are exploring acellular synthetic materials produced through extrusion bioprinting. These innovative materials rely on photocrosslinking to achieve the mechanical stability required for ocular use.
A recent breakthrough identifies a reliable method to monitor the photoinitiator Lithium Phenyl (2,4,6-Trimethylbenzoyl) Phosphinate (LAP). Although LAP is common in bioprinting, residual non-radicalized molecules can be cytotoxic to ocular cells. Scientists have now demonstrated that spectrophotometry can detect these residuals at a specific wavelength of 372 nm. This measurement depends directly on the LAP concentration within the hydrogel. Thus, it provides a simple way to evaluate crosslinked materials and prevent potential side effects. By correcting these formulations before implantation, clinicians can ensure better outcomes for patients receiving synthetic grafts.
This detection method simplifies the verification of synthetic graft safety. It ensures that the crosslinking process is complete and the final material is biocompatible. For medical practitioners in India, where the burden of corneal disease is high, such innovations represent a significant step toward lab-grown solutions. Monitoring chemical residuals effectively reduces the risk of inflammation and graft failure. Consequently, this technique bridges the gap between bioengineering and safe clinical application.
LAP is a water-soluble photoinitiator used to harden hydrogels during the bioprinting of synthetic corneal grafts using light.
Residual or non-radicalized LAP can cause cytotoxic effects, potentially damaging the surrounding ocular tissue after transplantation.
It measures the absorbance of the material at 372 nm, where the non-radicalized LAP crosslinker has specific characteristics that correlate with its concentration.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or substitute for professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Researchers have developed a spectrophotometric method to detect residual LAP photoinitiators in synthetic corneal grafts, improving safety in ophthalmology...
6 months ago

A breakthrough lethal C57BL/6 mouse model of Yezo virus infection recapitulates human leukopenia, thrombocytopenia, and hepatitis while uncovering sex-associated mortality and validating the therapeutic efficacy of favipiravir and ribavirin.
Today

A real-world cohort study evaluates anti-Müllerian hormone recovery and fertility outcomes in high-risk GTN patients treated with EMA/CO versus FAEV chemotherapy, demonstrating robust ovarian reserve recovery by six months post-treatment.
4 days back

A 4-question electrogram approach differentiates short-VA supraventricular tachycardia from ventricular tachycardia in patients with dual-chamber ICDs, preventing inappropriate therapy caused by atrial blanking.
Today

A multicenter prospective cohort study reveals that 54.1% of patients achieve clinically meaningful neuropathic pain relief after surgery for degenerative cervical myelopathy, driving substantial gains in motor function, mental health, and quality of life.
4 days back

The ferroptosis-immunity axis represents a critical driver of diabetic kidney disease progression. This review explores iron-dependent lipid peroxidation, innate immune cross-talk, emerging candidate biomarkers, and promising targeted therapies to delay renal decline alongside standard glycemic control.
4 days back